

BIOSPECIFICS TECHNOLOGIES CORP
 Form 4
 January 12, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Vogel Jeffrey Kenneth

2. Issuer Name and Ticker or Trading Symbol
 BIOSPECIFICS TECHNOLOGIES CORP [BSTC.PK]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 03/09/2006

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___ Other (specify below)

1 MEADOW DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___X___ Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

LAWRENCE, NY 11559

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/01/2006		P		500	A	\$ 2.05	422,652	I	See Footnote (1)
Common Stock	11/03/2006		P		2,000	A	\$ 2.6	424,652	I	See Footnote (2)
Common Stock	11/07/2006		P		1,000	A	\$ 3.15	425,652	I	See Footnote (3)
Common Stock	11/07/2006		P		2,000	A	\$ 3.25	427,652	I	See Footnote

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

									(4)
Common Stock	11/08/2006	P	1,000	A	\$ 3.25	428,652	I		See Footnote (5)
Common Stock	11/09/2006	P	2,000	A	\$ 3.75	430,652	I		See Footnote (6)
Common Stock	11/09/2006	P	1,000	A	\$ 3.5	431,652	I		See Footnote (7)
Common Stock	11/13/2006	P	2,000	A	\$ 3.75	433,652	I		See Footnote (8)
Common Stock	11/13/2006	P	1,000	A	\$ 3.6	434,652	I		See Footnote (9)
Common Stock	11/14/2006	P	3,000	A	\$ 4	437,652	I		See Footnote (10)
Common Stock	11/14/2006	P	1,000	A	\$ 3.87	438,652	I		See Footnote (11)
Common Stock	11/15/2006	P	2,000	A	\$ 4	440,652	I		See Footnote (12)
Common Stock	11/15/2006	P	300	A	\$ 3.95	440,952	I		See Footnote (13)
Common Stock	11/16/2006	P	1,000	A	\$ 4	441,952	I		See Footnote (14)
Common Stock	11/16/2006	P	1,000	A	\$ 3.99	442,952	I		See Footnote (15)
Common Stock	01/05/2007	P	1,000	A	\$ 4.35	443,952	I		See Footnote (16)
Common Stock	01/08/2007	P	1,000	A	\$ 4.5	444,952	I		See Footnote (17)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Vogel Jeffrey Kenneth 1 MEADOW DRIVE LAWRENCE, NY 11559		X		

Signatures

/s/ JEFFREY K. VOGEL 01/10/2007

Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes (i) 127,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and President of BioManagement Inc., the sole general partner of BioPartners LP).
- (2) Includes (i) 129,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder of and President of BioManagement, Inc., the sole general partner of BioPartners LP).
- (3) Includes (i) 130,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (4) Includes (i) 132,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (5) Includes (i) 133,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

- (6) Includes (i) 135,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (7) Includes (i) 136,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (8) Includes (i) 138,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (9) Includes (i) 139,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (10) Includes (i) 142,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (11) Includes (i) 143,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (12) Includes (i) 145,340 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (13) Includes (i) 145,640 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (14) Includes (i) 146,640 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (15) Includes (i) 147,640 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (16) Includes (i) 148,640 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).
- (17) Includes (i) 149,640 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by BioPartners LP (Jeffrey Vogel is the sole shareholder and president of BioManagement Inc., the sole general partner of BioPartners LP).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.